Loading…
Based on limited metadata, the FDA issued a Warning Letter to Jilin Shulan Synthetic Pharmaceutical Co. Ltd., a pharmaceutical manufacturer, on May 14, 2018. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The letter pertains to products categorized as "Other" and was issued through an unspecified FDA office, limiting clarity on the specific regulatory scope and product category involved.